|
1
|
Devic S: Warburg effect - a consequence or
the cause of carcinogenesis? J Cancer. 7:817–822. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Warburg O: On the origin of cancer cells.
Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
DeBerardinis RJ, Lum JJ, Hatzivassiliou G
and Thompson CB: The biology of cancer: Metabolic reprogramming
fuels cell growth and proliferation. Cell Metab. 7:11–20. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Heiden MG Vander, Cantley LC and Thompson
CB: Understanding the Warburg effect: The metabolic requirements of
cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
He XX, Tu SM, Lee MH and Yeung SC:
Thiazolidinediones and metformin associated with improved survival
of diabetic prostate cancer patients. Ann Oncol. 22:2640–2645.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
He X, Esteva F, Ensor J, Hortobagyi G, Lee
MH and Yeung SC: Metformin and thiazolidinediones are associated
with improved breast cancer-specific survival of diabetic women
with HER2+ breast cancer. Ann Oncol. 23:1771–1780. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vitale-Cross L, Molinolo AA, Martin D,
Younis RH, Maruyama T, Patel V, Chen W, Schneider A and Gutkind JS:
Metformin prevents the development of oral squamous cell carcinomas
from carcinogen-induced premalignant lesions. Cancer Prev Res
(Phila). 5:562–573. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lin YC, Wu MH, Wei TT, Lin YC, Huang WC,
Huang LY, Lin YT and Chen CC: Metformin sensitizes anticancer
effect of dasatinib in head and neck squamous cell carcinoma cells
through AMPK-dependent ER stress. Oncotarget. 5:298–308.
2014.PubMed/NCBI
|
|
9
|
Ma L, Niknejad N, GornHondermann I, Dayekh
K and Dimitroulakos J: Lovastatin induces multiple stress pathways
including LKB1/AMPK activation that regulate its cytotoxic effects
in squamous cell carcinoma cells. PLoS One. 7:e460552012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Patel H, Younis RH, Ord RA, Basile JR and
Schneider A: Differential expression of organic cation transporter
OCT3 in oral premalignant and malignant lesions: Potential
implications in the antineoplastic effects of metformin. J Oral
Pathol Med. 42:250–256. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sandulache VC, Skinner HD, Ow TJ, Zhang A,
Xia X, Luchak JM, Wong LJ, Pickering CR, Zhou G and Myers JN:
Individualizing antimetabolic treatment strategies for head and
neck squamous cell carcinoma based on TP53 mutational status.
Cancer. 118:711–721. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sandulache VC, Ow TJ, Pickering CR,
Frederick MJ, Zhou G, Fokt I, DavisMalesevich M, Priebe W and Myers
JN: Glucose, not glutamine, is the dominant energy source required
for proliferation and survival of head and neck squamous carcinoma
cells. Cancer. 117:2926–2938. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Skinner HD, Sandulache VC, Ow TJ, Meyn RE,
Yordy JS, Beadle BM, Fitzgerald AL, Giri U, Ang KK and Myers JN:
TP53 disruptive mutations lead to head and neck cancer treatment
failure through inhibition of radiation-induced senescence. Clin
Cancer Res. 18:290–300. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Knowler WC, BarrettConnor E, Fowler SE,
Hamman RF, Lachin JM, Walker EA and Nathan DM: Diabetes Prevention
Program Research Group: Reduction in the incidence of type 2
diabetes with lifestyle intervention or metformin. N Engl J Med.
346:393–403. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Giovannucci E, Harlan DM, Archer MC,
Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG and
Yee D: Diabetes and cancer: A consensus report. CA Cancer J Clin.
60:207–221. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ben Sahra I, Le Marchand-Brustel Y, Tanti
JF and Bost F: Metformin in cancer therapy: A new perspective for
an old antidiabetic drug? Mol Cancer Ther. 9:1092–1099. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Czyzyk A, Tawecki J, Sadowski J,
Ponikowska I and Szczepanik Z: Effect of biguanides on intestinal
absorption of glucose. Diabetes. 17:492–498. 1968. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hermann LS: Metformin: A review of its
pharmacological properties and therapeutic use. Diabetes Metab.
5:233–245. 1979.
|
|
19
|
Boussageon R, Supper I, BejanAngoulvant T,
Kellou N, Cucherat M, Boissel JP, Kassai B, Moreau A, Gueyffier F
and Cornu C: Reappraisal of metformin efficacy in the treatment of
type 2 diabetes: A meta-analysis of randomised controlled trials.
PLoS Med. 9:e10012042012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sogame Y, Kitamura A, Yabuki M, Komuro S
and Takano M: Transport of biguanides by human organic cation
transporter OCT2. Biomed Pharmacother. 67:425–430. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Noto H, Goto A, Tsujimoto T and Noda M:
Cancer risk in diabetic patients treated with metformin: A
systematic review and meta-analysis. PLoS One. 7:e334112012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Franciosi M, Lucisano G, Lapice E,
Strippoli GF, Pellegrini F and Nicolucci A: Metformin therapy and
risk of cancer in patients with type 2 diabetes: Systematic review.
PLoS One. 8:e715832013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sandulache VC, Hamblin JS, Skinner HD,
Kubik MW, Myers JN and Zevallos JP: Association between metformin
use and improved survival in patients with laryngeal squamous cell
carcinoma. Head Neck. 36:1039–1043. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pollak M: Insulin and insulin-like growth
factor signalling in neoplasia. Nat Rev Cancer. 8:915–928. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pollak M: Metformin and other biguanides
in oncology: Advancing the research agenda. Cancer Prev Res
(Phila). 3:1060–1065. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zakikhani M, Dowling R, Fantus IG,
Sonenberg N and Pollak M: Metformin is an AMP kinase-dependent
growth inhibitor for breast cancer cells. Cancer Res.
66:10269–10273. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dowling RJ, Zakikhani M, Fantus IG, Pollak
M and Sonenberg N: Metformin inhibits mammalian target of
rapamycin-dependent translation initiation in breast cancer cells.
Cancer Res. 67:10804–10812. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shaw RJ: LKB1 and AMP-activated protein
kinase control of mTOR signalling and growth. Acta Physiol (Oxf).
196:65–80. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Schmitz S and Machiels JP: Molecular
biology of squamous cell carcinoma of the head and neck: Relevance
and therapeutic implications. Expert Rev Anticancer Ther.
10:1471–1484. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Curry JM, Tuluc M, WhitakerMenezes D, Ames
JA, Anantharaman A, Butera A, Leiby B, Cognetti DM, Sotgia F,
Lisanti MP and Martinez-Outschoorn UE: Cancer metabolism, stemness
and tumor recurrence: MCT1 and MCT4 are functional biomarkers of
metabolic symbiosis in head and neck cancer. Cell Cycle.
12:1371–1384. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Warnakulasuriya S: Global epidemiology of
oral and oropharyngeal cancer. Oral Oncol. 45:309–316. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Petti S: Lifestyle risk factors for oral
cancer. Oral Oncol. 45:340–350. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Warnakulasuriya S: Causes of oral
cancer-an appraisal of controversies. Br Dent J. 207:471–475. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Belcher R, Hayes K, Fedewa S and Chen AY:
Current treatment of head and neck squamous cell cancer. J Surg
Oncol. 110:551–574. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Moher D, Liberati A, Tetzlaff J and Altman
DG: PRISMA Group: Preferred reporting items for systematic reviews
and meta-analyses: The PRISMA statement. Ann Intern Med.
151:264–269. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sobin LH, Gospodarowicz MK and Wittekind
C: TNM Classification of Malignant Tumours. 7th. Wiley-Blackwell;
New York, NY: 2009
|
|
37
|
Guyatt G, Oxman AD, Akl EA, Kunz R, Vist
G, Brozek J, Norris S, FalckYtter Y, Glasziou P, DeBeer H, et al:
GRADE guidelines: 1. Introduction-GRADE evidence profiles and
summary of findings tables. J Clin Epidemiol. 64:383–394. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Luo Q, Hu D, Hu S, Yan M, Sun Z and Chen
F: In vitro and in vivo anti-tumor effect of metformin as a novel
therapeutic agent in human oral squamous cell carcinoma. BMC
Cancer. 12:5172012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sikka A, Kaur M, Agarwal C, Deep G and
Agarwal R: Metformin suppresses growth of human head and neck
squamous cell carcinoma via global inhibition of protein
translation. Cell Cycle. 11:1374–1382. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Madera D, VitaleCross L, Martin D,
Schneider A, Molinolo AA, Gangane N, Carey TE, McHugh JB, Komarck
CM, Walline HM, et al: Prevention of tumor growth driven by PIK3CA
and HPV oncogenes by targeting mTOR signaling with metformin in
oral squamous carcinomas expressing OCT3. Cancer Prev Res (Phila).
8:197–207. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang F, Xu J, Xia F, Liu Z, Zhao S, Liu H
and Jiang Z: Effects of metformin on human oral cancer KB cell
proliferation and apoptosis in vitro. Nan Fang Yi Ke Da Xue Xue
Bao. 34:159–163. 2014.(In Chinese). PubMed/NCBI
|
|
42
|
Goodkind JR, Amer S, Christian C, Hess JM,
Bybee D, Isakson BL, Baca B, Ndayisenga M, Greene RN and Shantzek
C: Challenges and innovations in a community-based participatory
randomized controlled trial. Health Educ Behav. May 13–2016.(Epub
ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Xiao Z, Li CW, Shan J, Luo L, Feng L, Lu
J, Li SF, Long D and Li YP: Interventions to improve chronic
cyclosporine A nephrotoxicity through inhibiting renal cell
apoptosis: A systematic review. Chinese Med J (Engl).
126:3767–3774. 2013.
|
|
44
|
Pignon JP, le Maître A, Maillard E and
Bourhis J: MACH-NC Collaborative Group: Meta-analysis of
chemotherapy in head and neck cancer (MACH-NC): An update on 93
randomised trials and 17,346 patients. Radiother Oncol. 92:4–14.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Shah JP and Gil Z: Current concepts in
management of oral cancer-and Surgery. Oral Oncol. 45:394–401.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Salama JK, Haddad RI, Kies MS, Busse PM,
Dong L, Brizel DM, Eisbruch A, Tishler RB, Trotti AM and Garden AS:
Clinical practice guidance for radiotherapy planning after
induction chemotherapy in locoregionally advanced head-and-neck
cancer. Int J Radiat Oncol Biol Phys. 75:725–733. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Busch CJ, Tribius S, Schafhausen P and
Knecht R: The current role of systemic chemotherapy in the primary
treatment of head and neck cancer. Cancer Treat Rev. 41:217–221.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kundu SK and Nestor M: Targeted therapy in
head and neck cancer. Tumour Biol. 33:707–721. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Cicero AF, Tartagni E and Ertek S:
Metformin and its clinical use: New insights for an old drug in
clinical practice. Arch Med Sci. 8:907–917. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Segal ED, Yasmeen A, Beauchamp MC,
Rosenblatt J, Pollak M and Gotlieb WH: Relevance of the OCT1
transporter to the antineoplastic effect of biguanides. Biochem
Biophys Res Commun. 414:694–699. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Appleyard MV, Murray KE, Coates PJ,
Wullschleger S, Bray SE, Kernohan NM, Fleming S, Alessi DR and
Thompson AM: Phenformin as prophylaxis and therapy in breast cancer
xenografts. Br J Cancer. 106:1117–1122. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Lee JH, Kim TI, Jeon SM, Hong SP, Cheon JH
and Kim WH: The effects of metformin on the survival of colorectal
cancer patients with diabetes mellitus. Int J Cancer. 131:752–759.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Suissa S and Azoulay L: Metformin and the
risk of cancer: Time-related biases in observational studies.
Diabetes Care. 35:2665–2673. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Niraula S, Pond G, De Wit R, Eisenberger
M, Tannock IF and Joshua AM: Influence of concurrent medications on
outcomes of men with prostate cancer included in the TAX 327 study.
Can Urol Assoc J. 7:E74–E81. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Rêgo DF, Pavan LM, Elias ST, De Luca Canto
G and Guerra EN: Effects of metformin on head and neck cancer: A
systematic review. Oral Oncol. 51:416–422. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Novosyadlyy R and LeRoith D:
Hyperinsulinemia and type 2 diabetes. Impact on cancer. Cell Cycle.
9:1449–1450. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Ferguson RD, Novosyadlyy R, Fierz Y,
Alikhani N, Sun H, Yakar S and Leroith D: Hyperinsulinemia enhances
c-Myc-mediated mammary tumor development and advances metastatic
progression to the lung in a mouse model of type 2 diabetes. Breast
Cancer Res. 14:R82012. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Clayton PE, Banerjee I, Murray PG and
Renehan AG: Growth hormone, the insulin-like growth factor axis,
insulin and cancer risk. Nat Rev Endocrinol. 7:11–24. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Stattin P, Björ O, Ferrari P, Lukanova A,
Lenner P, Lindahl B, Hallmans G and Kaaks R: Prospective study of
hyperglyce-mia and cancer risk. Diabetes Care. 30:561–567. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Johnson JA and Bowker SL: Intensive
glycaemic control and cancer risk in type 2 diabetes: A
meta-analysis of major trials. Diabetologia. 54:25–31. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Chocarro-Calvo A, García-Martínez JM,
Ardila-González S, De la Vieja A and García-Jiménez C:
Glucose-induced β-catenin acetylation enhances Wnt signaling in
cancer. Mol Cell. 49:474–486. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Würth R, Barbieri F and Florio T: New
molecules and old drugs as emerging approaches to selectively
target human glioblastoma cancer stem cells. Biomed Res Int.
2014:1265862014. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Pernicova I and Korbonits M:
Metformin-mode of action and clinical implications for diabetes and
cancer. Nat Rev Endocrinol. 10:143–156. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Song CW, Lee H, Dings RP, Williams B,
Powers J, Santos TD, Choi BH and Park HJ: Metformin kills and
radiosensitizes cancer cells and preferentially kills cancer stem
cells. Sci Rep. 2:3622012. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Martini M, Ciraolo E, Gulluni F and Hirsch
E: Targeting PI3K in Cancer: Any good news? Front Oncol. 3:1082013.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Foster DA, Yellen P, Xu L and Saqcena M:
Regulation of G1 cell cycle progression: Distinguishing the
restriction point from a nutrient-sensing cell growth
checkpoint(s). Genes Cancer. 1:1124–1131. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Hamilton E and Infante JR: Targeting
CDK4/6 in patients with cancer. Cancer Treat Rev. 45:129–138. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Chu IM, Hengst L and Slingerland JM: The
Cdk inhibitor p27 in human cancer: Prognostic potential and
relevance to anticancer therapy. Nat Rev Cancer. 8:253–267. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Zhao L, Wen ZH, Jia CH, Li M, Luo SQ and
Bai XC: Metformin induces G1 cell cycle arrest and inhibits cell
proliferation in nasopharyngeal carcinoma cells. Anat Rec
(Hoboken). 294:1337–1343. 2011. View Article : Google Scholar : PubMed/NCBI
|
